Open platform to democratise longevity therapeutics R&D

Latest articles

Exclusive: “Mitlets” hold potential for mitochondria transfusion

Mitrix Bio believes recently discovered blood components may support transfusion of large quantities of healthy mitochondria from donor to patient. Earlier this year, we brought...

Optimise your body and mind by tackling cell stress

Want to live longer and heathier? Combating cell stress is an important first step on your longevity journey. It's a fast-paced, busy world, and we're...

Crypto – pulling a (Moon) Rabbit out a hat for longevity

Angel Versetti on why it makes sense to look at more experimental solutions for longevity. Earlier this week we brought you part one of our...

New webinar will explore the opportunity of ovarian longevity

What does delaying menopause mean in terms of investment activity, societal change and the technologies that will reshape the lives of multiple millions of...

Most read

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Editor's picks

Exclusive: “Mitlets” hold potential for mitochondria transfusion

Mitrix Bio believes recently discovered blood components may support transfusion of large quantities of healthy mitochondria from donor to patient. Earlier this year, we brought...

Optimise your body and mind by tackling cell stress

Want to live longer and heathier? Combating cell stress is an important first step on your longevity journey. It's a fast-paced, busy world, and we're...

Crypto – pulling a (Moon) Rabbit out a hat for longevity

Angel Versetti on why it makes sense to look at more experimental solutions for longevity. Earlier this week we brought you part one of our...

Click the globe for translations.

VitaDAO aims to extend human lifespan “by researching, financing, and commercializing longevity therapeutics in an open and democratic manner.”

An interesting new player has just emerged in the longevity funding ecosystem. VitaDAO is a platform for the acceleration of longevity R&D through “community-governed and decentralized drug development.” As a decentralized autonomous organization (DAO), VitaDAO is wholly owned and governed by its members.

Longevity.Technology: Despite recent growth in significant funding rounds for longevity ventures, early-stage funding is still a challenge, with intellectual property ownership a key issue. By leveraging crypto and blockchain technologies, VitaDAO is aiming to address this challenge head-on.

An open cooperative “that anyone can join”, VitaDAO aims to acquire, support and finance new therapeutics and research data in the longevity space. The collective will directly hold legal IP rights to these projects and intends to develop a portfolio of assets represented as non-fungible tokens (NFTs).

In addition to NFTs, VitaDAO leverages novel governance frameworks and financial engineering tools such as algorithmic automated market makers (AMMs) that run on the Ethereum blockchain.

VitaDAO

VitaDAO was initiated by Molecule.to and already involves a number of partners, including Ocean Protocol, Linum Labs, decentralized MATTER, and the Scheibye-Knudsen Lab at Copenhagen University, where the first project collaboration is happening.

“We’ve created VitaDAO to democratize the development of longevity therapeutics,” Tyler Golato, co-initiator of VitaDAO told us. “The goal is to enable drug development in an open, collaborative, and decentralized manner and include a broad community of stakeholders. With VitaDAO, anyone can contribute and co-own valuable therapeutics that will shape the future of longevity.”

The Scheibye-Knudsen lab project combines massive epidemiological datasets with wet-lab analyses to discover new drugs and drug targets for the extension of human lifespan and healthspan.

“The collaboration with Molecule has been in preparation for several years and it is therefore thrilling that we can finally reveal VitaDAO to the world,” says the lab’s leader, Dr Morten Scheibye-Knudsen. “The project is extremely interesting in the context of open science and since the project is openly sourced, we will provide the results openly and in an ongoing manner as they come in. I think this is a fantastic opportunity for the public to become engaged in how scientific drug discovery is made.”

VitaDAO

A whitepaper written by Golato and his Molecule co-founder Paul Kohlhaas, discusses current biopharma IP mechanisms, claiming that they “prevent the open sharing of research data, inherently disincentivizing collaboration and transparency.”

The paper goes on to say that the general public is large prevented from owning biopharma IP, “even though their tax dollars fund much of the early-stage development.”

VitaDAO aims to change this by allowing members of the public to contribute work or funds to joint the collective and become owners of its IP by purchasing “VITA tokens”. This could be either through contribution of funds, valuable research data or IP assets. Ownership of VITA tokens allows you to take part in decision-making and governance of VitaDAO’s research, indicate support for specific initiatives and govern its data repositories and IP portfolio.

In addition to acquiring and commissioning research, VitaDAO will own, develop and monetize the resulting IP assets. Longevity research projects can make funding requests to VitaDAO, which are voted on by its members. If successful, funding is provided in exchange for an ownership stake in the resulting IP.

Interested in joining the VitaDAO community? You can sign up to its groups on Telegram or Discord.

Image credit: Pete LinforthPixabay
Danny Sullivan
Contributing Editor Danny has worked in technology communications for more than 15 years, spanning Europe and North America. From bionics and lasers to software and pharmaceuticals – and everything in between – he’s covered it all. Danny has wide experience of technology publishing and technical writing and has specific interest in the transfer from idea to market.

Most popular

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Tree of Longevity – understanding how supplements work

Pathways? Hallmarks? Biomarkers? Understanding the longevity supplements lingo can help you make better choices for your healthspan. Longevity supplements differ from other 'generic supplements' as...

Related articles

Crypto – pulling a (Moon) Rabbit out a hat for longevity

Angel Versetti on why it makes sense to look at more experimental solutions for longevity. Earlier this week we brought you part one of our...

New webinar will explore the opportunity of ovarian longevity

What does delaying menopause mean in terms of investment activity, societal change and the technologies that will reshape the lives of multiple millions of...

Buck Institute awarded $12.7m to join senescence network

NIH award to join SenNet, the Cellular Senescence Network, will enable Buck scientists to identify and characterise senescent cells – recognised as a driver...

Michael Antonov: longevity is all about tackling true unknowns

The Co-founder of Formic Ventures is using logic and innovation to drive the longevity sector forward. Michael Antonov is a serial entrepreneur and philanthropist who...

Deep learning platform seeks near-term indications of age-related diseases

Arrive co-founder talks combining aging cell biology, drug screening and deep learning technology in the quest to discover novel antiaging targets. Silicon Valley and Singapore-based...